Compare
Seres Therapeutics, Inc. vs Elite Pharmaceuticals Inc vs Monopar Therapeutics vs Prelude Therapeutics Inc
| Latest fiscal year | Seres Therapeutics, Inc. MCRBRevenue covers only part of its income (partial revenue) | Elite Pharmaceuticals Inc ELTP | Monopar Therapeutics MNPR | Prelude Therapeutics Inc PRLD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $148.87M | $0 | $12.14M |
| Revenue growth (YoY) | n/a | +77.1% | n/a | +73.4% |
| Gross margin | n/a | 50.4% | n/a | n/a |
| Operating margin | n/a | 33.0% | n/a | -861.3% |
| Net margin | n/a | 30.1% | n/a | -819.6% |
| Net income | $5.70M | $44.87M | -$13.72M | -$99.50M |
| EPS (Diluted) | $0.64 | $0.03 | n/a | -$1.29 |
| Operating cash flow | $1.12M | $23.75M | -$12.20M | -$56.30M |
| Free cash flow | $865.0K | $22.82M | n/a | -$56.37M |
| Cash & equivalents | $45.77M | n/a | $61.83M | $35.26M |
| Total assets | $138.19M | $138.29M | $140.72M | $141.31M |
| Total liabilities | $93.97M | $39.41M | $2.89M | $72.68M |
| Shareholders' equity | $44.22M | $98.88M | $137.83M | $68.64M |
| Return on year-end equity | 12.9% | 45.4% | -10.0% | -145.0% |
| Shares outstanding | 9.56M | 1.08B | 6.69M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Seres Therapeutics, Inc. | Elite Pharmaceuticals Inc | Monopar Therapeutics | Prelude Therapeutics Inc |
|---|---|---|---|---|
| Latest | n/a | $148.87M Ended 2026-03-31 | $0 Ended 2025-12-31 | $12.14M Ended 2025-12-31 |
| 1 year earlier | n/a | $84.04M Ended 2025-03-31 | $0 Ended 2024-12-31 | $7.00M Ended 2024-12-31 |
| 2 years earlier | n/a | $56.63M Ended 2024-03-31 | n/a | n/a |
| 3 years earlier | n/a | $34.16M Ended 2023-03-31 | n/a | n/a |
| 4 years earlier | n/a | $32.26M Ended 2022-03-31 | n/a | n/a |